Maher Nasser
Interventional Cardiology · Houston, TXNPI 1588762157
Payments from drug & device makers
Across 146 payments — averaging $21.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$393
- Novartis$335
- Amgen$333
- Merck$249
- Medtronic$218
- Johnson & Johnson$210
- plus $1K from 15 others
What the payments were for
- Food & beverage$3,04698%
- Education$512%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 16 | $393 |
| Novartis | 15 | $335 |
| Amgen | 14 | $333 |
| Merck | 16 | $249 |
| Medtronic | 3 | $218 |
| Johnson & Johnson | 11 | $210 |
| Sanofi-aventis U.S. LLC | 11 | $201 |
| AstraZeneca | 11 | $171 |
| Boehringer Ingelheim | 7 | $160 |
| Esperion Therapeutics, Inc. | 9 | $153 |
| Pfizer | 9 | $139 |
| Arbor Pharmaceuticals, Inc. | 8 | $125 |
| Abbott | 3 | $87 |
| Heartflow, Inc. | 1 | $83 |
| E.r. Squibb & Sons, L.L.C. | 4 | $72 |
| Novo Nordisk | 3 | $63 |
| Davol Inc. | 1 | $26 |
| Boston Scientific | 1 | $23 |
| Cardinal Health 200 LLC | 1 | $23 |
| Bardy Diagnostics, Inc. | 1 | $20 |
| Chiesi USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Reveal LINQ$124
- Vascepa$120
How this compares
$3,098 in reported general payments places this provider in the 15th percentile of 686 interventional cardiology providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 11 | $14,687 |
| XareltoRivaroxaban | 17 | $12,563 |
| Metoprolol Succinate | 77 | $1,778 |
| Nebivolol Hcl | 19 | $956 |
| Atorvastatin Calcium | 68 | $535 |
| ClopidogrelClopidogrel Bisulfate | 38 | $529 |
| Carvedilol | 35 | $371 |
| Rosuvastatin Calcium | 26 | $360 |
| Fenofibrate | 13 | $351 |
| Levothyroxine Sodium | 20 | $291 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 22 | $277 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 15 | $256 |
| Amlodipine Besylate | 35 | $196 |
| Hydrochlorothiazide | 20 | $120 |
| Lisinopril | 11 | $34 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $139 | $14,68711 claims |
| Johnson & JohnsonXarelto | $210 | $12,56317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Houston
- Neal KleimanHouston$4.8M
- Juan GranadaHouston$4.3M
- Abhijeet DhobleHouston$2.7M
- John IsaacHouston$1.8M
- Amir KashaniHouston$1.3M
- Biswajit KarHouston$785K
- Michele SartoriHouston$603K
- Guilherme SilvaHouston$516K
- Sachin KumarHouston$446K
- Marwan JumeanHouston$427K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.